Publicacións en colaboración con investigadores/as de Mayo Clinic (50)

2024

  1. Elevated Troponins after COVID-19 Hospitalization and Long-Term COVID-19 Symptoms: Incidence, Prognosis, and Clinical Outcomes—Results from a Multi-Center International Prospective Registry (HOPE-2)

    Journal of Clinical Medicine, Vol. 13, Núm. 9

2023

  1. A phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of sarilumab in patients with giant cell arteritis

    Arthritis Research and Therapy, Vol. 25, Núm. 1

  2. Association Between Race/Ethnicity and COVID-19 Outcomes in Systemic Lupus Erythematosus Patients From the United States: Data From the COVID-19 Global Rheumatology Alliance

    Arthritis Care and Research, Vol. 75, Núm. 1, pp. 53-60

  3. Escaping the Long Shadow Cast by Agranulocytosis: Reflections on Clozapine Pharmacovigilance Focused on the United Kingdom

    Journal of Clinical Psychopharmacology, Vol. 43, Núm. 3, pp. 239-245

  4. Measurement Properties of Outcome Instruments for Large-Vessel Vasculitis: A Systematic Literature Review

    The Journal of rheumatology, Vol. 50, Núm. 6, pp. 789-798

  5. Mortality by age, gene and gender in carriers of pathogenic mismatch repair gene variants receiving surveillance for early cancer diagnosis and treatment: a report from the prospective Lynch syndrome database

    eClinicalMedicine, Vol. 58

  6. Post-COVID-19 Symptoms and Heart Disease: Incidence, Prognostic Factors, Outcomes and Vaccination: Results from a Multi-Center International Prospective Registry (HOPE 2)

    Journal of Clinical Medicine, Vol. 12, Núm. 2

2022

  1. An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels

    Pharmacopsychiatry, Vol. 55, Núm. 2, pp. 73-86

  2. Characteristics and Outcomes of People With Gout Hospitalized Due to COVID-19: Data From the COVID-19 Global Rheumatology Alliance Physician-Reported Registry

    ACR Open Rheumatology, Vol. 4, Núm. 11, pp. 948-953

  3. Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance

    Annals of the rheumatic diseases, Vol. 81, Núm. 7, pp. 970-978

  4. Development of a Prediction Model for COVID-19 Acute Respiratory Distress Syndrome in Patients With Rheumatic Diseases: Results From the Global Rheumatology Alliance Registry

    ACR Open Rheumatology, Vol. 4, Núm. 10, pp. 872-882

  5. Environmental and societal factors associated with COVID-19-related death in people with rheumatic disease: an observational study

    The Lancet Rheumatology, Vol. 4, Núm. 9, pp. e603-e613

  6. Erratum: Correction: An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels (Pharmacopsychiatry (2022) 55 2 (73-86))

    Pharmacopsychiatry

  7. Galactose epimerase deficiency: lessons from the GalNet registry

    Orphanet journal of rare diseases, Vol. 17, Núm. 1, pp. 331

  8. Leadless pacemaker implant, anticoagulation status, and outcomes: Results from the Micra Transcatheter Pacing System Post-Approval Registry

    Heart Rhythm, Vol. 19, Núm. 2, pp. 228-234

  9. Psychometric properties of outcome measurement instruments for ANCA-associated vasculitis: a systematic literature review

    Rheumatology (Oxford, England), Vol. 61, Núm. 12, pp. 4603-4618

  10. Publisher Correction: Stroke genetics informs drug discovery and risk prediction across ancestries (Nature, (2022), 611, 7934, (115-123), 10.1038/s41586-022-05165-3)

    Nature

  11. Stroke genetics informs drug discovery and risk prediction across ancestries

    Nature, Vol. 611, Núm. 7934, pp. 115-123

  12. Variations in management of A3 and A4 cervical spine fractures as designated by the AO Spine Subaxial Injury Classification System

    Journal of Neurosurgery: Spine, Vol. 36, Núm. 1, pp. 99-112

2021

  1. Association between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death among Patients with Immune-Mediated Inflammatory Disease and COVID-19

    JAMA Network Open